CTLA-4 (cytotoxic T-lymphocyte-associated protein 4)
CTLA-4, or cytotoxic T-lymphocyte-associated protein 4, is a protein found on the surface of T cells, which are crucial parts of our immune system. It acts as a checkpoint that regulates immune responses by inhibiting T cell activation. This means that when CTLA-4 binds to certain molecules on other cells, it can dampen the immune response, preventing T cells from attacking healthy tissues. In cancer therapy, drugs that block CTLA-4 can enhance the immune system’s ability to recognize and attack tumor cells, offering a way to improve treatments for some cancers.
Additional Insights
-
CTLA-4, or Cytotoxic T-lymphocyte-associated protein 4, is a protein found on the surface of T cells, which are essential for the immune system. It plays a crucial role in regulating immune responses by acting as a brake, preventing T cells from becoming too active and attacking the body or causing inflammation. By keeping the immune response in check, CTLA-4 helps maintain balance, protecting against autoimmune diseases. In cancer treatment, drugs that block CTLA-4 are used to enhance the immune system's ability to recognize and attack tumor cells, making it an important target in immunotherapy.
-
CTLA-4, or Cytotoxic T-Lymphocyte Associated Protein 4, is a protein found on the surface of T cells, which are crucial for our immune system. It acts as a kind of "brake" that helps regulate immune responses. When T cells are activated to fight infections or cancer, CTLA-4 inhibits their activity, preventing them from becoming overly aggressive and harming healthy tissue. This balancing act is essential for maintaining immune system homeostasis. Researchers are exploring CTLA-4 in cancer therapies to enhance the immune response against tumors by blocking its action, potentially improving treatment effectiveness.